• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Employer plan costs up 10% in a struggling US economy

Article

New survey shows financial pain for employers and employees with few good options to manage the trend

CHICAGO-Healthcare costs for employer-sponsored health plans are expected to increase by more than 10% in 2010, according to a survey of more than 60 health insurance companies.

Aon Consulting, surveyed plans serving more than 100 million insured individuals.

"While we're seeing a slight decrease in the trend rates, it's still at double digits, and this year, it's compounded by a struggling economy, layoffs and salary freezes or reductions," says Tom Lerche, healthcare practice leader for Aon Consulting.

THREE WAYS TO SHAPE PLANS

Because the spiraling cost trend for the next 12 months is expected to increase 10% or more, plan sponsors are focused on tactics and strategies to reduce medical trend to mid- to low-single digits.

"Given the financial pain on both companies and employees from the recession, employers are re-examining changes in health plan options, plans design, and clinical solutions which may have been rejected in 2008," Lerche says. "In particular, employers are conducting audits to saving money in the short run and designing and implementing wellness strategies for long-term impact."

According to Lerche, there are three ways most plan sponsors may shape their plan offerings for 2010:

Additionally, prescription drug cost increases are expected. The Aon survey projects drug costs will increase 9.3% in 2010, slightly lower than the 9.4% trend rate one year ago.

Related Videos
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Video 8 - "Risk and Value-Based Contracting for Prescription Drug Therapeutics and Manufacturer’s Support in Utilization"
Video 7 - "Prescribing Prescription Drug Therapeutics: Factors for Providers and Payers to Consider"
Related Content
© 2024 MJH Life Sciences

All rights reserved.